Evidence map›Paper›PMID 41088366›Full record

ArticleJournal of translational medicine2025

Exome sequencing reveals new insights into the germline landscape of inflammatory breast cancer among Tunisian patients.

Maroua Boujemaa, Yosr Hamdi, Souhir Guidara, Amal Souissi, Hanen Bouaziz, Nesrine Mejri, Samir Aloulou, Najet Mahjoub, Kais Chaabane, Hana Hakim and 14 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Diagnostics (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Maroua BoujemaaLaboratory of Biomedical Genomics and Oncogenetics (LR16IPT05), Université Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur, 1002 Tunis-Belvédère, Tunis, Tunisia.ORCID 0000-0001-7409-9240
Yosr HamdiLaboratory of Biomedical Genomics and Oncogenetics (LR16IPT05), Université Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur, 1002 Tunis-Belvédère, Tunis, Tunisia. yosr.hamdi@pasteur.utm.tn.ORCID 0000-0002-2815-1834
Souhir GuidaraDepartment of Human Genetics, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia.
Amal SouissiLaboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, University of Sfax, Sfax, Tunisia.ORCID 0000-0003-3838-1876
Hanen BouazizLaboratory of Biomedical Genomics and Oncogenetics (LR16IPT05), Université Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur, 1002 Tunis-Belvédère, Tunis, Tunisia.ORCID 0000-0001-5885-1252
Nesrine MejriMedical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.ORCID 0000-0001-7647-5027
Samir AloulouDepartment of Medical Oncology,, Mohamed Ben Sassi University Hospital of Gabes, Faculty of Medicine, Sfax, Tunisia.
Najet MahjoubDepartment of Gynecology, University Hospital Hédi Chaker, Sfax, Tunisia.
Kais ChaabaneDepartment of Gynecology, University Hospital Hédi Chaker, Sfax, Tunisia.
Hana HakimDepartment of Gynecology, University Hospital Hédi Chaker, Sfax, Tunisia.
Hamouda BoussenMedical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.ORCID 0000-0002-4131-8475
Tarek Ben DhiabDepartment of Carcinological Surgery, Salah Azaiez Institute, Tunis, Tunisia.ORCID 0009-0007-4456-638X
Salma KamounDepartment of Pathology, Salah Azaiez Institute, 1006, Tunis, Tunisia.ORCID 0000-0003-0175-6136
Rahma AyadiPathology Department, Abderrahmen Mami Hospital, Ariana, Tunisia.
Maha DrissDepartment of Pathology, Salah Azaiez Institute, 1006, Tunis, Tunisia.
Aida AyadiPathology Department, Abderrahmen Mami Hospital, Ariana, Tunisia.
Fouzia RadouaniChlamydiae and Mycoplasmas Laboratory, Research Department, Institut Pasteur du Maroc, Casablanca, Morocco.ORCID 0000-0002-6221-2661
Meryem FakhkhariResearch Laboratory in Oral Biology and Biotechnology, Faculty of Dental Medicine, Mohammed V University in Rabat, Rabat, Morocco.ORCID 0000-0001-8227-1549
Meriem KhyattiLaboratory of Viral Oncology, Institut Pasteur du Maroc, Casablanca, Morocco.ORCID 0000-0001-9376-4322
Sonia AbdelhakLaboratory of Biomedical Genomics and Oncogenetics (LR16IPT05), Université Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur, 1002 Tunis-Belvédère, Tunis, Tunisia.ORCID 0000-0001-8466-5525
Khalid SadkiLaboratory of Viral Oncology, Institut Pasteur du Maroc, Casablanca, Morocco.ORCID 0000-0002-9224-5050
Mohamed Samir BoubakerLaboratory of Biomedical Genomics and Oncogenetics (LR16IPT05), Université Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur, 1002 Tunis-Belvédère, Tunis, Tunisia.
Ahmed RebaiLaboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, University of Sfax, Sfax, Tunisia.ORCID 0000-0002-8954-8683
Boutheina CherifLaboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, University of Sfax, Sfax, Tunisia.ORCID 0000-0002-6923-2948

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, characterized by distinct clinicopathological features and a relatively high frequency in North African countries. While several studies have explored the genetic basis of breast cancer, limited research has looked into the specific genetic features of this aggressive form. This study aims to investigate the genetic factors associated with IBC in North Africa, particularly among Tunisian patients.

methodsWhole exome sequencing was performed for 13 patients with IBC. Clinicopathological data have been collected to assess the phenotype-genotype correlation. Both germline point mutations and copy number variations (CNVs) were analyzed. Genes and variants were prioritized through phenotype and genotype-driven approaches. Variants were filtered based on pathogenicity predictions and ACMG classification. A Gene-Disease association analysis was conducted using DisGeNET data and the VarElect online tool to select candidate genes most likely involved in disease onset. The predictive and prognostic values of the relevant genes were assessed using publicly available datasets.

resultsOur investigations revealed relevant genetic variants within established cancer predisposing genes, inflammatory pathways, and potential candidate predisposing genes, including BRCA2 c.1794_1798del, a novel mutation in RAD54L gene (c.1712T > C) and c.555_559del in IFNAR2 gene. CNVs in ABRAXAS1, XRCC2 and FANC genes were identified. We have also found that the high expression levels of RAD54L and MTHFR are correlated with good survival rates. The genetic makeup of IBC seems to be very heterogeneous. For the same patient, we have detected several relevant variants that might explain disease development and progression, and this was consistent with the family history of cancer observed in the investigated families.

conclusionsOur findings revealed a complex and heterogeneous genetic background of IBC in the Tunisian population that might contribute to disease susceptibility and impact disease prognosis. The genetic features of IBC presented in this study provide valuable insights into the molecular mechanisms underlying the disease offering not only a deeper understanding within the context of Tunisia but also shedding light on its relevance to other North African populations characterized by similar epidemiological and genetic features.

Indexed as

Exome SequencingGerm-Line MutationInflammatory Breast NeoplasmsAdultAgedDNA Copy Number VariationsFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansMiddle AgedPrognosisTunisiaClinicopathological featuresGenetic landscapeInflammatory breast cancerWhole exome sequencing

Identifiers

PMID41088366
PMCPMC12522356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.